Literature DB >> 6286122

Phase II study on DON in patients with previously treated advanced lung cancer.

R T Eagan, S Frytak, W C Nichols, E T Creagan, J N Ingle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6286122

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  9 in total

1.  Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs.

Authors:  Lukáš Tenora; Jesse Alt; Ranjeet P Dash; Alexandra J Gadiano; Kateřina Novotná; Vijayabhaskar Veeravalli; Jenny Lam; Quinn R Kirkpatrick; Kathryn M Lemberg; Pavel Majer; Rana Rais; Barbara S Slusher
Journal:  J Med Chem       Date:  2019-03-29       Impact factor: 7.446

2.  Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion.

Authors:  Robert D Leone; Liang Zhao; Judson M Englert; Im-Meng Sun; Min-Hee Oh; Im-Hong Sun; Matthew L Arwood; Ian A Bettencourt; Chirag H Patel; Jiayu Wen; Ada Tam; Richard L Blosser; Eva Prchalova; Jesse Alt; Rana Rais; Barbara S Slusher; Jonathan D Powell
Journal:  Science       Date:  2019-11-07       Impact factor: 47.728

Review 3.  A glutamine 'tug-of-war': targets to manipulate glutamine metabolism for cancer immunotherapy.

Authors:  Laura J Pallett; Sarah Dimeloe; Linda V Sinclair; Adam J Byrne; Anna Schurich
Journal:  Immunother Adv       Date:  2021-06-01

Review 4.  Targeting Energy Metabolism in Cancer Treatment.

Authors:  Joanna Kubik; Ewelina Humeniuk; Grzegorz Adamczuk; Barbara Madej-Czerwonka; Agnieszka Korga-Plewko
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

Review 5.  Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.

Authors:  Diana Cervantes-Madrid; Yair Romero; Alfonso Dueñas-González
Journal:  Biomed Res Int       Date:  2015-09-06       Impact factor: 3.411

6.  Glutamine antagonism attenuates physical and cognitive deficits in a model of MS.

Authors:  Kristen R Hollinger; Matthew D Smith; Leslie A Kirby; Eva Prchalova; Jesse Alt; Rana Rais; Peter A Calabresi; Barbara S Slusher
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-08-29

Review 7.  Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy.

Authors:  Angèle Luby; Marie-Clotilde Alves-Guerra
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

8.  Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement.

Authors:  Jesse Alt; Sadakatali S Gori; Kathryn M Lemberg; Arindom Pal; Vijayabhaskar Veeravalli; Ying Wu; Joanna M H Aguilar; Ranjeet P Dash; Lukáš Tenora; Pavel Majer; Qi Sun; Barbara S Slusher; Rana Rais
Journal:  Curr Drug Metab       Date:  2021       Impact factor: 3.731

Review 9.  We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine.

Authors:  Kathryn M Lemberg; James J Vornov; Rana Rais; Barbara S Slusher
Journal:  Mol Cancer Ther       Date:  2018-09       Impact factor: 6.009
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.